文献速递神经外科与老年麻醉心胸血管麻醉

惰性气体氩和氙对获得性脑损伤的神经保护作用:临床前系统评价与Meta分析

Neuroprotection by the noble gases argon and xenon as treatments for acquired brain injury: a preclinical systematic review and meta-analysis.
PubMed 文献 · Br J Anaesth · 2022-06-07

该临床前系统评价与Meta分析纳入32项研究(氩14项、氙18项,共1384只动物),评估氩和氙对获得性脑损伤的神经保护作用。结果显示氩和氙均具有显著神经保护效应,氙的效应量大于氩,且氙在包括CPB模型后仍显著优于氩。

要点

  • 氩和氙在临床前脑损伤模型中均显示显著神经保护作用(P<0.001)。
  • 氙的神经保护效应量(34.1%)高于氩(18.1%),且差异显著(P<0.001)。
  • 氙在包含CPB模型时效应量为27.4%,仍显著优于氩。

核心结论

  • 临床前证据支持氩和氙作为获得性脑损伤的神经保护治疗,且氙总体效果优于氩。

研究设计与样本

  • 系统检索MEDLINE和Embase数据库后,对临床前研究进行配对和分层Meta分析,共纳入32项研究(氩14项、氙18项),涉及1384只动物(小鼠、大鼠和猪模型)。

主要发现

  • 氩(CA、TBI、卒中)总体效应量为18.1%(95%CI 8.1-28.1%),氙(CA、TBI、卒中)为34.1%(95%CI 24.7-43.6%),均P<0.001。
  • 氙在包含CPB模型(CPB、CA、TBI、卒中)时效应量为27.4%(95%CI 11.5-43.3%)。
  • 氙无论是否包含CPB模型,均显著比氩更具保护作用(P<0.001)。

临床怎么用

  • 当前临床前证据提示氙和氩可能作为获得性脑损伤的神经保护治疗,但需进一步临床转化验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The noble gases argon and xenon are potential novel neuroprotective treatments for acquired brain injuries. Xenon has already undergone early-stage clinical trials in the treatment of ischaemic brain injuries, with mixed results. Argon has yet to progress to clinical trials as a treatment for brain injury. Here, we aim to synthesise the results of preclinical studies evaluating argon and xenon as neuroprotective therapies for brain injuries. METHODS: After a systematic review of the MEDLINE and Embase databases, we carried out a pairwise and stratified meta-analysis. Heterogeneity was examined by subgroup analysis, funnel plot asymmetry, and Egger's regression. RESULTS: A total of 32 studies were identified, 14 for argon and 18 for xenon, involving measurements from 1384 animals, including murine, rat, and porcine models. Brain injury models included ischaemic brain injury after cardiac arrest (CA), neurological injury after cardiopulmonary bypass (CPB), traumatic brain injury (TBI), and ischaemic stroke. Both argon and xenon had significant (P<0.001), positive neuroprotective effect sizes. The overall effect size for argon (CA, TBI, stroke) was 18.1% (95% confidence interval [CI], 8.1-28.1%), and for xenon (CA, TBI, stroke) was 34.1% (95% CI, 24.7-43.6%). Including the CPB model, only present for xenon, the xenon effect size (CPB, CA, TBI, stroke) was 27.4% (95% CI, 11.5-43.3%). Xenon, both with and without the CPB model, was significantly (P<0.001) more protective than argon. CONCLUSIONS: These findings provide evidence to support the use of xenon and argon as neuroprotective treatments for acquired brain injuries. Current evidence suggests that xenon is more efficacious than argon overall.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Liang M, Ahmad F, Dickinson R, et al. Neuroprotection by the noble gases argon and xenon as treatments for acquired brain injury: a preclinical systematic review and meta-analysis. Br J Anaesth. 2022. PMID: 35688658. doi:10.1016/j.bja.2022.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。